1 **Journal:** Journal of Neuroscience Methods; *Original Research*

2
3 **Semi-automated Rapid Quantification of Brain Vessel Density**
4 **Utilizing Fluorescent Microscopy**

5
6 *Kaci A. Bohn^{a,b}, *Chris E. Adkins^{a,c}, Rajendar K. Mittapalli^a, Tori B. Terrell-Hall^c,
7 Afroz S. Mohammad^c, Neal Shah^c, Emma L. Dolan^c, Mohamed I. Nounou^{a,d,e}, and Paul
8 R. Lockman^{a,c,‡}

9
10 * These authors contributed equally to the manuscript

11
12
13 ^a Texas Tech University Health Sciences Center, School of Pharmacy, Department of
14 Pharmaceutical Sciences, Amarillo, Texas 79106-1712;

15 ^b Harding University, College of Pharmacy, Department of Pharmaceutical Sciences,
16 Searcy, Arkansas 72149-12230

17 ^c West Virginia University Health Sciences Center, School of Pharmacy, Department of
18 Pharmaceutical Sciences, Morgantown, WV, 26506, USA

19 ^d Appalachian College of Pharmacy, Oakwood, VA, 24631, USA

20 ^e Alexandria University, Faculty of Pharmacy, Department of Pharmaceutics, Alexandria,
21 Egypt

22
23 **Corresponding Author:**

24 ‡ Paul R. Lockman, BSN, Ph.D.
25 West Virginia University Health Sciences Center
26 School of Pharmacy
27 Department of Pharmaceutical Sciences
28 1 Medical Center Drive
29 Morgantown, West Virginia, 26506-9050
30 Phone: 304-293-0944
31 Email: prlockman@hsc.wvu.edu

32
33
34 Total Text Pages: 28

35 Number of Figures: 5 (2-B&W; 3-Color)

36 Number of Tables: 0

Abstract

Background: Measurement of vascular density has significant value in characterizing healthy and diseased tissue, particularly in brain where vascular density varies among regions. Further, an understanding of brain vessel size helps distinguish between capillaries and larger vessels like arterioles and venules. Unfortunately, few cutting edge methodologies are available to laboratories to rapidly quantify vessel density.

New Method: We developed a rapid microscopic method, which quantifies the numbers and diameters of blood vessels in brain. Utilizing this method we characterized vascular density of five brain regions in both mice and rats, in two tumor models, using three tracers.

Results: We observed the number of sections/mm² in various brain regions: genu of corpus callosum 161 ± 7 , hippocampus 266 ± 18 , superior colliculus 300 ± 24 , frontal cortex 391 ± 55 , and inferior colliculus 692 ± 18 (n=5 animals). Regional brain data were not significantly different between species ($p>0.05$) or when using different tracers (70kDa and 2000kDa Texas Red; $p>0.05$). Vascular density decreased (62-79%) in preclinical brain metastases but increased (62%) a rat glioma model.

Comparison with Existing Methods: Our values were similar ($p>0.05$) to published literature. We applied this method to brain-tumors and observed brain metastases of breast cancer to have a ~2.5-fold reduction ($p>0.05$) in vessels/mm² compared to normal cortical regions. In contrast, vascular density in a glioma model was significantly higher (sections/mm² 736 ± 84 ; $p<0.05$).

Conclusions: In summary, we present a vascular density counting method that is rapid, sensitive, and uses fluorescence microscopy without antibodies.

60 **Keywords**

61 Vessel Density, Fluorescent Microscopy, Metastases, Immunohistochemistry, TX Red,
62 Indocyanine Green

63

64

65

66

67

68 **Abbreviations**

69 BBB: Blood Brain Barrier

70 SD: Sprague-Dawley rats

71 CD-1: Charles River CD-1 Swiss mice

72 F344: Fisher 344 rats

73 VD: Vessel/Vascular Density

74 kDa: kilodalton

75 ICG: Indocyanine Green

76 eGFP: Enhanced Green Fluorescent Protein

77 MW: molecular weight

78 TX Red: Texas Red

79 FITC: fluorescein isothiocyanate

1. Introduction

Vascular density varies from organ to organ, with some tissues such as lung containing 6-fold higher values than heart (Targan et al., 2003). The brain is a highly vascularized organ, although vessel density varies among regions i.e., thalamus contains 460 vessels/mm² which is double the number of blood vessels per unit of tissue compared to the superior colliculus (Klein et al., 1986; Wu et al., 2004). Alterations in vessel density are noted in pathological conditions like ischemia, aging, and cancer (Aronen et al., 1994; Eberhard et al., 2000; Farkas and Luiten, 2001; Mann et al., 1986). Clinically, low vascular density is used as a measure of a lack of developmental progress and as an indicator of cerebral palsy or mental retardation in infants (Miyawaki et al., 1998). Similarly a higher density of brain vasculature in stroke patients has been correlated with improved progress and survival due to the increased blood flow to the damaged area (Krupinski et al., 1993). In contrast, higher vessel densities have been associated with lower patient outcome in several types of cancer (Bevilacqua et al., 1995; Nico et al., 2008; Uzzan et al., 2004; Weidner et al., 1993).

Currently, several methods are used to calculate vessel density including the Chalkley method, the Weidner approach, and capillary perfusion of fluorescein isothiocyanate (FITC)-labeled globulin or dextran. Each of these techniques involves manual counting of vessels, which has the limitations of being highly time consuming and difficult to reproduce (Chalkley, 1943; Gobel et al., 1991; Weidner et al., 1991). Human error can be a significant confounding variable in the identification of individual vessels. For example, when the thickness of the tissue sample is so thin that only a small portion of a vessel might be visible, variable human judgement can lead to errors in

counting (Nico et al., 2008; Simpson et al., 1996). A review of 43 studies which evaluated vascular density and patient prognosis in breast cancer revealed that only three studies utilized a completely automated methodology to assess vessel density. Of the remaining 40 studies, four used a combined manual and automated system (Uzzan et al., 2004).

To address the limitations of time and human error, we have developed a semi-automated rapid methodology to quickly and accurately assess vascular density of brain tissue. Briefly, the method consists of injecting a large molecular weight fluorescent marker into the peripheral vasculature, allowing the dye to circulate in the blood for approximately 60-120 seconds followed by immediate sacrifice, removal of the brain from the skull within 45 seconds, and immediate freezing in isopentane. Similar to previously published work, in our initial studies, we used the large vascular-impermeant fluorescent dextrans, Texas Red 2000kDa and Texas Red 70kDa, to count the normal brain vascular density of both mice and rats. In subsequent studies we used indocyanine green (ICG), which upon entry to circulation becomes bound to albumin. Albumin is rapidly trapped in the vasculature, and has been used previously as a vascular marker (Habazettl et al., 2010). In studies using Texas Red, we observed that vascular density values in rat and mouse brain showed no significant difference from previously published results using manual counting methods. To expand the application of this method to pathological conditions, we incorporated an experimental brain metastases of breast cancer and an implanted glioma model. Comparison of the metastatic and glioma models showed striking differences in vascular density. Brain metastases generally had a significantly lower number of capillaries per unit of tissue, compared to normal brain,

whereas the highly aggressive RG-2 glioma model was 5-6 fold higher in density. In summary, we demonstrate that this methodology has the ability to efficiently and accurately calculate vascular density in normal and pathological brain tissue. Further, this method is easily transferable to numerous labs, which may increase vascular density counting as a variable in neurological studies.

2. Methods

2.1. Chemicals

Lysine fixable dextrans Texas Red 2000kDa MW and Texas Red 70kDa MW were purchased from Molecular Probes (Invitrogen, Eugene, OR). Indocyanine green (ICG) and all other analytical grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

2.2. Cell Culture

Human metastatic breast cancer cells transfected with enhanced green fluorescent protein (eGFP) over-expressing Her2 (MDA-MB-231-BR-Her2) and rat glioma (RG-2) cells were cultured in DMEM supplemented with 10% FBS (MDA required Zeocin 300 µg per 500 mL media, Invitrogen). All cells were used in passages 1-10 and maintained at 37°C with 5% CO₂. For preparation of cells for injection, cells were grown to 70% confluency, trypsinized, and rinsed twice in 4°C PBS to remove all traces of serum. Cells were resuspended in serum free 4°C DMEM and placed on ice. All cell lines were kindly provided by the laboratory of Dr. Patricia Steeg at the National Cancer Institute.

2.3. *Animals*

Male F344 rats (220-330 g; n=12), male CD-1 mice (25-30 g, n=12), and female NuNu mice (~25 g; n=12) were obtained from Charles River Laboratories (Kingston, NY); 287Sato/J (Tie-2 GFP; n=3) transgenic female mice were purchased from Jackson Laboratories (Bar Harbor, ME). All studies were approved by the Animal Care and Use Committee at Texas Tech University Health Sciences Center, and conducted in accordance with the 1996 NIH Guide for the Care and Use of Laboratory Animals.

2.4. *In Vivo Tumor Models*

For development of metastases, female NuNu mice were anesthetized with isoflurane and inoculated with the breast cancer cell line MDA-MB-231-BR-Her2 (1.75×10^5 cells) in the left cardiac ventricle with the use of a stereotaxic device (Stoelting, Wood Dale, IL) and sterile 28 gauge tuberculin syringes, as previously described (Lockman et al., 2010). Tumor cells seeded the brain and were allowed to grow for 4-6 weeks. Intracranial implantation in F344 rats of RG-2 cells (1.0×10^5 cells) in 5 μ L was accomplished using a stereotaxic frame to inoculate into the caudate-putamen complex at coordinates of 4.5mm lateral to bregma and 4.5mm deep (Ningaraj et al., 2003) after anaesthetizing with ketamine (75-100 mg/kg) and xylazine (6-8 mg/kg). Animals recovered from tumor cell inoculation within 15 minutes. All animals were monitored for signs of lethargy, weight loss, paralysis, and hunched posture. Median survival was 18 days for F344 rats and 32 days for NuNu mice.

2.5. *Injection of Vascular Markers*

One of the two fluorescent markers (Texas Red MW 2000kDa or Texas Red MW 70kDa) was injected intravenously into F344 rats or CD-1 mice (1.5 mg/animal body weight) via femoral vein using a 31-gauge tuberculin syringe and allowed to circulate for 2 minutes. In tumor studies, on day 30 ± 2 (MDA-MB-231-BR-Her2) and day 7 (RG-2), ICG (1.5 mg/animal), was injected intravenously and allowed to circulate 1 minute. Animals were then euthanized via decapitation under anesthesia (ketamine/xylazine), the brain tissue was rapidly removed (< 45 seconds) and flash frozen in isopentane (-65°C). Care was taken to remove brain rapidly since slower removal may cause changes in the spatial distribution of tracers (Jay et al., 1988; Williams et al., 1991). Sagittal brains sections were sliced at $6\mu\text{m}$ thickness using a cryostat (Shandon Cryotome®) at -30°C . Slices were mounted on glass slides and air-dried with no mounting media or coverslip. Fluorescence images were then obtained from specific brain regions (genu of corpus callosum, hippocampus, superior and inferior colliculus, frontal cortex, caudate putamen) aided by an anatomical atlas (Paxinos and Franklin, 1997; Paxinos and Watson, 1998). The vessel density analysis utilizing the different molecular weight markers and ICG was accomplished by analyzing a subset of tissue sections from each of the brain regions.

2.6. *Fluorescence imaging*

Fluorescence was observed with an Olympus IX81 stereo microscope (Olympus America Inc., Center Valley, PA) using a 40x objective ($\text{NA} = 0.6$). A 100 Watt short arc mercury lamp was used as the fluorescence light source. Texas Red dextran fluorescence was measured via a DsRed Sputter filter (Chroma Technology: cat # U-M49004XL: excitation 560 nm, emission 645 nm). Likewise, ICG fluorescence was recorded using a

Cy7 filter (Chroma Technology: cat # 41009XL: excitation 740 nm, emission 780 nm). A dichromatic mirror prevented emitted light with a wavelength shorter than 565 nm (Texas Red fluorescence) or 770 nm (ICG) to reach the microscope's camera. Images were acquired with a monochromatic 12-bit cooled CCD camera (Retiga 4000R; QImaging, Surrey, British Columbia) connected to a computer running Slidebook™ 5.0 analysis software (Intelligent Imaging Innovations "3I", Denver).

2.7. Vessel Density and Size Determination

Slices were analyzed using a binary masking methodology based upon fluorescence to define the vessel locations (Slidebook™ 5.0). Regions of interest were delineated with the help of an anatomical atlas (Paxinos and Franklin, 1997; Paxinos and Watson, 1998) and tissue autofluorescence. Binary masks were created by identifying areas of fluorescent intensity (for both Texas Red and ICG) exceeding a 3-fold threshold above background fluorescence in each channel. Objects exceeding this threshold that were smaller than 1 micron squared (μm^2) were excluded from quantitation. Background intensities for each channel were defined by identifying the background peak on the intensity distribution histogram of each image; background intensities were equivalent among each slice evaluated in this study. Briefly, binary masking consisted of defining the vessel based on Texas Red and ICG fluorescence on a voxel by voxel basis. If Texas Red or ICG fluorescence was present (> 3 -fold above background) the voxel was considered to belong to a vessel. Vessel densities were calculated per area (mm^2). Vessel diameters were determined utilizing the same software and masking system to identify the minor axis length of each object.

2.8. Statistical Analysis

One-way ANOVA analysis followed by Bonferroni's multiple comparison test was used for vessel density data analysis in control brains during development of the method. For all data, errors are reported as standard error of the mean unless otherwise indicated. For analysis of tumor vessel density, ANOVA analysis with Dunnett's post-test was used to compare values within each brain region. This test was also used to determine significant differences in tumor vessel diameter. Differences were considered statistically significant at the $p < 0.05$ level (GraphPad Prism 5.0).

3. Results

3.1. Fluorescence Microscopy Observations of Vessel Density

To develop an efficient technique to identify and calculate brain vessel density, we first perfused transgenic mice expressing Tie-2 driven GFP in brain vasculature to determine whether fluorescent tracers would mark structures other than the vasculature. Intracardially perfused TX Red 70kDa dextran remained within the vasculature and did not stain compartments or structures other than vessels within the brain (**Fig 1**). We then utilized both rat and mouse injected with Texas Red dextran MW 2000kDa or Texas Red MW 70kDa (circulation time of 2 minutes), or ICG (circulation time of 1 minute) for tumor studies. Objects of interest were based on fluorescence sum intensity (> 3 -fold above background) and subsequently counted for each brain region. Representative images are shown of vessel density (F344 and CD-1, 40x magnification) in various brain regions of high vascular density (ie: inferior colliculus with a greater number of vessels)

and low vascular density (ie: genu of corpus callosum with fewer vessels) (**Fig. 2A**). **Fig. 2B** is a representative image of frontal cortex brain vasculature as identified with red fluorescence (Texas Red 70kDa, 12x magnification); and **Fig. 2C** shows the overlay of the binary masking technique employed by the software to identify vessels. Smaller red objects are attributed to a minute part of the vessel appearing in the tissue slice.

3.2. Vessel Density Calculations

To calculate the density of fluorescently-labeled blood vessels, comprehensive digital microscopy software (Slidebook™ 5.0) was used to select fluorescent objects voxel by voxel and calculate the total number of blood vessels per area (vessels/mm²). **Fig. 3A** shows the local densities of perfused capillaries as calculated by Gobel et al (1991), who determined vascular densities using two different markers: FITC-globulin and FITC-dextran (both injected in the femoral vein), and FITC-globulin injection into the tail vein. Observed densities varied from ~148 vessels/mm² in the genu of corpus callosum to ~658 vessels/mm² in the inferior colliculus. To determine if the current method using fluorescence microscopy would achieve similar values, Texas Red MW 2000kDa was injected into the femoral vein (circulation of 2 minutes). Vessels/mm² calculated in F344 rats were: genu of corpus callosum 161 ± 7, hippocampus 266 ± 18, superior colliculus 300 ± 24, frontal cortex 391 ± 55, and inferior colliculus 692 ± 18 (n= 5 animals) (**Fig. 3B**). Vascular densities in previous reports (Gobel et. al, 1991) using identical section thicknesses (6µm) fell within one standard deviation of values obtained in the current study using the Texas Red 2000kDa marker in F344 rats.

In our second set of experiments, we translated this method to calculate vascular density in the mouse brain, which is a species often used for cancer models but for which there are limited data on brain vascular density. In addition, we compared results observed with Texas Red 2000kDa to those obtained using a smaller molecular weight marker (Texas Red 70kDa) that is known to be vascular impermeant in the 120 second circulation time frame. Values obtained with Texas Red 2000kDa in the mouse (CD-1) brain were: genu of corpus callosum 137 ± 19 , hippocampus 230 ± 19 , superior colliculus 413 ± 35 , frontal cortex 444 ± 36 , and inferior colliculus 680 ± 41 (vessels/mm²) (**Fig. 3C**). Injection of Texas Red 70kDa in CD-1 mice resulted in similar values (One way ANOVA followed by Bonferroni's multiple comparison's test; $p > 0.05$) as Texas Red 2000kDa, ranging from 155 ± 11 in the genu of corpus callosum to 711 ± 22 in the inferior colliculus (**Fig. 3D**). While the values within the mouse were similar ($p > 0.05$) using either tracer, a small increase in vascular density was seen in the superior colliculus and frontal cortex regions in the mouse brain compared to the F344 rat, though it was not significantly different (One way ANOVA followed by Bonferroni's multiple comparison test; $p > 0.05$).

3.3. Vessel Size Distribution in Brain

For size analysis of fluorescently labeled vessels, we separated objects of interest (vessels filled with Texas Red 2000kDa) into categories based on minor axis length (diameter). Within both rat and mouse brains, the majority of vessels were in the vessel size range of $<10 \mu\text{m}$ (~81% and ~94%, respectively) (**Fig. 4**). The size range with the greatest number of vessels was 2-4.99 μm (rat had 168 vessels and mouse had 90). The vessel size range (~10-14 μm) contained ~12% and ~4.8% of vessels counted in the rat

and mouse brains, respectively. The rat model produced a greater number of vessels with diameter in the size range of 5-7.99 μm compared with the mouse ($p= 0.037$) and is consistent with previous reports (Howell et al., 1974). All other vessel sizes were not different between mouse and rat in this study. While previous studies (Heinsen and Heinsen, 1983) agree with these observation, differences in methodology and technology have been known to introduce variability in these measurements of vascular density (Burns et al., 1981; Hunziker et al., 1979).

3.4 Vascular Density Values are Decreased in Preclinical Brain Metastases and Elevated in Implanted Gliomas Regardless of Location

After validation of the current counting technique in normal brain in both rat and mouse, we applied it to two pathological models of brain cancer: experimental brain metastases of breast cancer (MDA-MB-231-BR-Her2) and an intracranially implanted rat glioma model (RG-2). For the brain metastases model, 175,000 MDA-MB-231-BR-Her2 breast cancer cells were injected into the left cardiac ventricle of anesthetized NuNu female mice and allowed to metastasize to brain. To initiate the glioma model, 1.0×10^5 stably eGFP-transfected rat glioma (RG-2) cells were intracranially implanted in the caudate putamen of anesthetized F344 rats using a stereotaxic apparatus (Stoelting Co.; Wood Dale, IL). Lesions were allowed to develop (~30 days for MDA-MB-231-BR-Her2 and ~7 days for the RG-2 model) and indocyanine green (ICG) was injected intravenously as a near-infrared tracer (Habazettl et al., 2010). Representative images of ICG labeled vasculature are shown here, obtained from normal brain parenchyma (**Fig. 5A**), a MDA-MB-231-BR-Her2 metastatic lesion (**Fig. 5B**) and an experimental glioma (**Fig. 5C**). Qualitatively, a decrease in vessel density is observed in experimental brain

metastases (**Fig. 5B**) compared to the higher densities seen in normal corresponding brain regions (**Fig. 5A**) and the experimental glioma model (**Fig. 5C**). As shown in **Fig. 5D** there is a quantitatively significant ($p < 0.001$) ~2.5-fold reduction in vessels/mm² in metastatic lesions (MDA-MB-231-BR-Her2: 168 ± 37) compared with normal brain parenchyma (443 ± 21) in cortical regions. Similarly, vascular density values of experimental lesions in the caudate putamen region of the brain, were also significantly ($p < 0.001$) decreased (MDA-MB-231-BR-Her2: 97 ± 7) compared to the corresponding normal brain region (455 ± 26). In addition, the time frame for development of lesions corresponded to the vessel density and aggressiveness of the lesion ie., ~32 days for metastases compared to ~7 days RG-2 gliomas; and vascular density values of the experimental metastases (~138 vessels/mm² average) were substantially less than ($p < 0.001$) that observed in the glioma model (736 ± 84).

4. Discussion

There are several limitations in current methodologies used to evaluate vascular density. The Chalkley method involves hand counting nuclei within randomly achieved hot spots, but is used to achieve ratios of volumes rather than actual cell numbers (Chalkley, 1943). A second method is immunohistochemical staining of tissue for vessel density analysis. Limitations of this method include differing protocols from one lab to the next such as fixation techniques, antibody dilutions, and long storage periods, all of which can result in protein loss and contribute to human error (Bertheau et al., 1998; Jacobs et al., 1996; Walker, 2006). Lastly, vascular density has been manually calculated using perfused FITC labeled fibronectin or FITC conjugated dextran. While all three

methods yield similar results, they all involve time consuming manual calculations (Gobel et al., 1991; Klein et al., 1986). In contrast with the previous methodologies, the current technique put forth in this report utilizes comprehensive digital microscopy software to evaluate microvessel density, yields immediate results thereby reducing counting time, and substantially reduces variability introduced by human observation.

Fluorescent dye based determination of vascular density has become widely employed for quantification. However, a major problem associated with fluorescent markers is photobleaching (the photochemical destruction of the fluorophore due to prolonged periods of exposure to a light source) (Giloh and Sedat, 1982). Common fluorescence dyes such as FITC are prone to rapid bleaching when exposed to excitation light sources, such as the 100 Watt short arc mercury lamp used in this study, and are sensitive to pH and moisture during sample storage (Benchabib et al., 1996); newer generation fluorescence probes exhibit improved photostability and are less susceptible to photobleaching (Lefevre et al., 1996; Titus et al., 1982). To prevent photobleaching in this study, we limited the period of exposure of the fluorophores to 800 milliseconds with a green fluorescent filter and kept the slides in the dark at all times. Focusing of the images was performed in the dark utilizing a small amount of visible light to ensure no exposure to the excitation light until the moment of image capture. Using this technique, the observed total fluorescence intensity emanating from the vasculature did not change more than 7% during imaging (data not shown).

To address the limitation of the potential vascular extravasation of the marker, we selected fluorescent markers either bound to large dextrans (Texas Red 2000kDa and

346 Texas Red 70kDa) or to albumin. Vascular extravasation must be addressed since it
347 would potentially increase vessel density counts and could affect the morphological size
348 analysis of vessels in brain. It has been previously shown that large molecular weight
349 markers are trapped within the vasculature of the brain (Pardridge, 2005). For this study,
350 we chose a dextran conjugated Texas Red tracer which, because of its size and
351 hydrophilic nature, exhibits poor extravasation into brain across an intact BBB. Unlike
352 many classical fluorescent dyes such as fluorescein sodium and FITC, more than 95% of
353 indocyanin green binds protein in plasma (Haglund et al., 1994) which restricts it to the
354 vasculature in brain and making ICG an optimal vascular marker. In our study, we used a
355 circulation time of two minutes, to balance an adequate perfusion of the brain vasculature
356 with minimal to no leakage of the marker into the brain parenchyma (Reese and
357 Karnovsky, 1967). Microscopic evaluation of our data revealed that all vascular sections
358 had sharp fluorescence “edges” indicating the dyes were limited to the vascular space.
359 This method may be applied easily into other laboratories as fluorescent dextrans of
360 varying sizes are often used as vascular markers (Hoffmann et al., 2011), given their
361 price and relative ease of administration. Brain tissue autofluorescence reduces the
362 signal-to-noise ratio and degrades sharp contrasting structure when imaging fluorescent
363 probes emitting in the 340–525nm wavelength ranges (Billinton and Knight, 2001;
364 Duong and Han, 2013). Unlike many classical fluorescence probes such as FITC, Texas
365 Red dextran and ICG are well suited for quantification of vascular density since their
366 emission peak wavelengths occur outside and further red-shifted than most of the spectra
367 of brain autofluorescence (Molitoris et al., 2002). The use of these red-shifted fluorescent
368 probes enhances the signal-to-noise and structural contrast in brain tissue samples.

Early studies in counting brain vascular density presented conflicting numbers, with some groups presenting much lower data than others. While it was recognized that there was potential human error in counting, others groups postulated that not all capillary beds in brain were open during all times. One hypothesis was discussed which suggested that brain capillaries opened and closed over time creating “reserve” capillaries, that could be opened to deliver oxygen and glucose during increased metabolic demand (Klein et al., 1986). A second hypothesis suggested that the opening and closing of capillaries occurred fairly quickly in response to a “stop and go” movement of blood (Ozanne, 1975). However, as vacular density studies progressed, values calculated using a method of capillary perfusion of FITC labeled globulin were compared to values identified with immunofluorescence labeling, and no significant difference in various brain regions were noted (Gobel et al., 1991). Other studies reported similar results using gamma globulin coupled fluorophores and various circulation times, and eventually, it was accepted that brain capillaries appear to be constantly perfused under normal physiological conditions (Klein et al., 1986). Our data are similar to the mentioned studies other than that our calculations are performed with semi-automated software.

This study reports accurate vascular density numbers for CD-1 mice and immune compromised mice (cortical and caudate-putamen regions), which up to now has been significantly lacking in the literature. Most studies that calculate vascular densities for pathological purposes employ a ratio method, reporting the vessel surface area divided by the brain parenchyma area. For this study, we did not follow the classical design-based stereological approach (Dockery and Fraher, 2007; Muhlfeld, 2014; Walchli et al., 2015).

However, our method differed from stereological approaches only by the method in which the tissue sections were cut so that we could identify specific brain regions in which measurements were acquired. All tissue slices were sectioned at equivalent slice thickness and equidistant from another to adhere as close to a stereological approach as possible. In an effort provide comparable data to literature (Gobel et al., 1991), we chose not to transform the vessel densities to a number per unit volume. Of note, it has been determined that microvessels in the cortex of rodents are oriented isotropically (Eins and Bar, 1978) and, therefore, reduces methodological bias in this study. The vascular densities categorized by vessel diameter between mouse and rat had minor variations that were not significantly different except for vessel sizes of 5-7.99 μm in diameter; these results are similar to previous studies (Heinsen and Heinsen, 1983). The small variations observed can likely be attributed to structural differences between rat and mouse nervous tissue as a result of strain-related differences in vascular architecture (Beckmann et al., 1999; Burns et al., 1981; Hunziker et al., 1979; Kitagawa et al., 1998).

To apply a semi-automated technique in a pathological model, we performed vascular density counts in mice with experimental brain metastases and an RG-2 rat glioma implantation model. Vessel density counts in MDA-MB-231-BR-Her2 metastatic lesions within the cortical region were reduced 62% compared to normal brain parenchyma. Vessel densities in metastases in the caudate-putamen complex were decreased to densities 21% of control brain values and 13% of RG-2 gliomas. Implanted gliomas were highly vascular with densities ~ 1.5 fold greater than normal brain parenchyma. Gliomas are considered highly angiogenic and aggressive with increased

414 vascular density; and metastases have been shown to have vessel densities at only
415 fractions of corresponding normal tissue (Ribatti, 2008; Yano et al., 2000).

416 In conclusion, the data presented herein confirm the validity of a semi-automated
417 rapid methodology utilizing fluorescence microscopy and comprehensive software to
418 efficiently evaluate brain vessel density. This study puts forth data showing congruence
419 of this semi-automated technique to previously published manual counts. Application of
420 the current technique to a pathological model demonstrated decreased vessel density
421 within metastatic lesions and increased density in cranially implanted gliomas. Since
422 analysis of vessel density plays a critical role in several disease states, this new technique
423 will aid in more efficient data acquisition in both the clinical and laboratory settings.

5. Figure Legends

Figure 1: Perfusion of fluorescent tracers label and remain restricted to vessels in brain. A representative image of Tie-2 driven GFP expression (A) in brain vasculature perfused with TX Red 70kD dextran (B). The overlay (C) of each channel indicates good colocalization and no tracer associated with structures other than brain vasculature. Scale bar = 100µm.

Figure 2: Fluorescence images showing perfused capillaries labeled with TX Red dextrans in different brain regions. **Panel A** representative images of capillaries after 2 min in vivo circulation of TX Red 2000 kDa or TX Red 70 kDa (1.5 mg/kg) in F344 rat and CD-1 mouse models (rows). Regional vascular variability is evident by the greater number of red fluorescing objects within the inferior colliculus compared to the genu of corpus callosum. **Panels B and C:** Images illustrating binary masking in CD-1 mouse frontal cortex region. **Panel B** illustrates TX Red 70 kDa marked vessels in a 6 µm section. **Panel C** is the binary mask overlay on images of panel B, identifying capillary sections based on fluorescent intensity.

Figure 3: Vascular density of various brain regions. The quantified vascular density of various brain regions are shown . **Panel A** represents vascular density in male SD rats (data reproduced with permission from (Gobel et al., 1991)). **Panel B** shows vascular density in F344 rats using (2000kDa TxRed), **Panel C** CD-1 mice (2000kDa TxRed), and **Panel D** CD-1 mice (70kDa TxRed). No significant differences ($p>0.05$) in

vessel density was observed between previously published work and species. Data were analyzed using one-way ANOVA followed by Bonferroni's multiple comparison test. All values represent mean $\pm$ SEM (n=3-6).

Figure 4: Size distribution of vascular diameter in control regions of rat and mouse brain. Data shows comparison between F344 (grey bar) and CD-1 (black bar) vessel diameters. The F344 rat model showed a greater number of vessels in the size range 5-7.99 μm compared to the CD-1 mouse model (* $p= 0.037$); however, no significant differences ($p>0.05$) were observed in the distribution of other size ranges. All data include an n=3-5 mice/rats per group and an n>3 brain slices analyzed per rodent. All data represent the number of vessels per mm^2 (mean $\pm$ SEM).

Figure 5: Vascular density is decreased in metastatic lesions compared to normal brain parenchyma regardless of location. Representative fluorescence images of GFP (left panel), ICG (center panel), and overlay (right panel) in normal brain (**row A**), metastatic tumor (**row B**), and RG2 glioma regions (**row C**). GFP labelled metastases (*M*) or glioma (*G*) are shown with adjacent tissue separated by white dashed lines. Scale bars = 200 μm . (**D**) Vascular density of cortex and metastases (1st and 2nd column) in corresponding cortex region. The 3rd-5th columns show vascular density of caudate-putamen, metastases, and glioblastoma in corresponding brain region (caudate-putamen). Statistical significance in cortical samples was determined using Student's t-

467 test; *** $p < 0.001$, $n=3-5$. Significance in caudate putamen region was determined using
468 ANOVA with Bonferroni's multiple comparison's test; *** $p < 0.0001$, $n=3-5$.

469

470

471 **Figure 1**

472

473 **Figure 2**

474

475

Figure 3

Figure 5

484 **Acknowledgements**

485 This research was supported by grants from the National Cancer Institute
486 (R01CA166067-01A1) and Department of Defense Breast Cancer Research Program
487 (W81XWH-062-0033) awarded to P. Lockman. Additional support for this research was
488 provided by WVCTSI through the National Institute of General Medical Sciences of the
489 National Institutes of Health (WVCTSI Award: U54GM104942, and the CoBRE P30
490 GM103488).

491

References

- Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. *Radiology*, 1994; 191: 41-51.
- Beckmann N, Stirnimann R, Bochen D. High-resolution magnetic resonance angiography of the mouse brain: application to murine focal cerebral ischemia models. *J Magn Reson*, 1999; 140: 442-50.
- Benchab M, Delorme R, Pluvinau M, Bryon PA, Souchier C. Evaluation of five green fluorescence-emitting streptavidin-conjugated fluorochromes for use in immunofluorescence microscopy. *Histochemistry and cell biology*, 1996; 106: 253-6.
- Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Verola O, Lesourd A, Sene C, Brocheriou C, Janin A. Variability of immunohistochemical reactivity on stored paraffin slides. *J Clin Pathol*, 1998; 51: 370-4.
- Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study. *Breast Cancer Res Treat*, 1995; 36: 205-17.
- Billinton N, Knight AW. Seeing the wood through the trees: a review of techniques for distinguishing green fluorescent protein from endogenous autofluorescence. *Anal Biochem*, 2001; 291: 175-97.
- Burns EM, Kruckeberg TW, Gaetano PK. Changes with age in cerebral capillary morphology. *Neurobiology of aging*, 1981; 2: 283-91.
- Chalkley HW. Method for the Quantitative Morphologic Analysis of Tissues. *Journal of the National Cancer Institute*, 1943; 4: 47-53.
- Dockery P, Fraher J. The quantification of vascular beds: a stereological approach. *Experimental and molecular pathology*, 2007; 82: 110-20.
- Duong H, Han M. A multispectral LED array for the reduction of background autofluorescence in brain tissue. *Journal of neuroscience methods*, 2013; 220: 46-54.
- Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. *Cancer Res*, 2000; 60: 1388-93.
- Eins S, Bar T. Orientation distribution of blood vessels in central nervous tissue. *Sonderb Prakt Metallogr*, 1978; 8: 381-8.

- 526 Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease.
527 Prog Neurobiol, 2001; 64: 575-611.
- 528 Giloh H, Sedat JW. Fluorescence microscopy: reduced photobleaching of rhodamine and
529 fluorescein protein conjugates by n-propyl gallate. Science, 1982; 217: 1252-5.
- 530 Gobel U, Theilen H, Schrock H, Kuschinsky W. Dynamics of capillary perfusion in the
531 brain. Blood Vessels, 1991; 28: 190-6.
- 532 Habazettl H, Athanasopoulos D, Kuebler WM, Wagner H, Roussos C, Wagner PD,
533 Ungruhe J, Zakynthinos S, Vogiatzis I. Near-infrared spectroscopy and indocyanine
534 green derived blood flow index for noninvasive measurement of muscle perfusion during
535 exercise. J Appl Physiol, 2010; 108: 962-7.
- 536 Haglund MM, Hochman DW, Spence AM, Berger MS. Enhanced optical imaging of rat
537 gliomas and tumor margins. Neurosurgery, 1994; 35: 930-40; discussion 40-1.
- 538 Heinsen H, Heinsen YL. Cerebellar capillaries. Qualitative and quantitative observations
539 in young and senile rats. Anat Embryol (Berl), 1983; 168: 101-16.
- 540 Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. High and
541 Low Molecular Weight Fluorescein Isothiocyanate (FITC)-Dextran to Assess Blood-
542 Brain Barrier Disruption: Technical Considerations. Transl Stroke Res, 2011; 2: 106-11.
- 543 Howell WH, Fulton JF, Ruch TC, Patton HD. Physiology and biophysics: Circulation,
544 respiration and fluid balance. Saunders, 1974.
- 545 Hunziker O, Abdel'Al S, Schulz U. The aging human cerebral cortex: a stereological
546 characterization of changes in the capillary net. J Gerontol, 1979; 34: 345-50.
- 547 Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining
548 intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst, 1996; 88: 1054-9.
- 549 Jay TM, Lucignani G, Crane AM, Jehle J, Sokoloff L. Measurement of local cerebral
550 blood flow with [14C]iodoantipyrine in the mouse. J Cereb Blood Flow Metab, 1988; 8:
551 121-9.
- 552 Kitagawa K, Matsumoto M, Yang G, Mabuchi T, Yagita Y, Hori M, Yanagihara T.
553 Cerebral ischemia after bilateral carotid artery occlusion and intraluminal suture
554 occlusion in mice: evaluation of the patency of the posterior communicating artery. J
555 Cereb Blood Flow Metab, 1998; 18: 570-9.
- 556 Klein B, Kuschinsky W, Schrock H, Vetterlein F. Interdependency of local capillary
557 density, blood flow, and metabolism in rat brains. Am J Physiol, 1986; 251: H1333-40.

558 Krupinski J, Kaluza J, Kumar P, Wang M, Kumar S. Prognostic value of blood vessel
559 density in ischaemic stroke. *Lancet*, 1993; 342: 742.

560 Lefevre C, Kang HC, Haugland RP, Malekzadeh N, Arttamangkul S, Haugland RP.
561 Texas Res-X and rhodamine Red-X, new derivatives of sulforhodamine 101 and
562 lissamine rhodamine B with improved labeling and fluorescence properties. *Bioconjug*
563 *Chem*, 1996; 7: 482-9.

564 Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE,
565 Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR.
566 Heterogeneous blood-tumor barrier permeability determines drug efficacy in
567 experimental brain metastases of breast cancer. *Clinical cancer research : an official*
568 *journal of the American Association for Cancer Research*, 2010; 16: 5664-78.

569 Mann DM, Eaves NR, Marcyniuk B, Yates PO. Quantitative changes in cerebral cortical
570 microvasculature in ageing and dementia. *Neurobiol Aging*, 1986; 7: 321-30.

571 Miyawaki T, Matsui K, Takashima S. Developmental characteristics of vessel density in
572 the human fetal and infant brains. *Early Hum Dev*, 1998; 53: 65-72.

573 Molitoris BA, Sandoval R, Sutton TA. Endothelial injury and dysfunction in ischemic
574 acute renal failure. *Crit Care Med*, 2002; 30: S235-40.

575 Muhlfeld C. Quantitative morphology of the vascularisation of organs: A stereological
576 approach illustrated using the cardiac circulation. *Ann Anat*, 2014; 196: 12-9.

577 Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, Ribatti D. Evaluation of
578 microvascular density in tumors: pro and contra. *Histol Histopathol*, 2008; 23: 601-7.

579 Ningaraj NS, Rao MK, Black KL. Adenosine 5'-triphosphate-sensitive potassium
580 channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor
581 model. *Cancer research*, 2003; 63: 8899-911.

582 Ozanne G, Vilnis, V., Severinghaus, J. Implications of oxygen waves and synchrony for
583 regulation of cerebral microcirculation. In Harper AM, editor. *Blood flow and*
584 *metabolism in the brain: proceedings of the 7th International Symposium on Cerebral*
585 *Blood Flow and Metabolism*, Aviemore, Scotland, June 17th-20th, 1975. Churchill
586 Livingstone: Aviemore, Scotland, 1975.

587 Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. *NeuroRx*,
588 2005; 2: 3-14.

589 Paxinos G, Franklin KB. *The mouse brain in stereotaxic coordinates*, 2nd ed. Academic
590 Press, 1997.

591 Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 4th ed. Academic Press:
592 San Diego, 1998.

593 Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to
594 exogenous peroxidase. The Journal of cell biology, 1967; 34: 207-17.

595 Ribatti DaV, A. Overview of Angiogenesis During Tumor Growth. In Folkman WDFaJ,
596 editor. Angiogenesis: An Integrative Approach from Science to Medicine. Springer
597 Science+Business Media, LLC: New York, NY, 2008: 161-8.

598 Simpson JF, Ahn C, Battifora H, Esteban JM. Endothelial area as a prognostic indicator
599 for invasive breast carcinoma. Cancer, 1996; 77: 2077-85.

600 Targan SR, Shanahan F, Karp LC. Inflammatory bowel disease : from bench to bedside,
601 2nd ed. Kluwer Academic Pub.: Dordrecht ; Boston, 2003.

602 Titus JA, Haugland R, Sharrow SO, Segal DM. Texas Red, a hydrophilic, red-emitting
603 fluorophore for use with fluorescein in dual parameter flow microfluorometric and
604 fluorescence microscopic studies. Journal of immunological methods, 1982; 50: 193-204.

605 Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor
606 in women with breast cancer: a systematic review of the literature and meta-analysis.
607 Cancer research, 2004; 64: 2941-55.

608 Walchli T, Mateos JM, Weinman O, Babic D, Regli L, Hoerstrup SP, Gerhardt H,
609 Schwab ME, Vogel J. Quantitative assessment of angiogenesis, perfused blood vessels
610 and endothelial tip cells in the postnatal mouse brain. Nature protocols, 2015; 10: 53-74.

611 Walker RA. Quantification of immunohistochemistry--issues concerning methods, utility
612 and semiquantitative assessment I. Histopathology, 2006; 49: 406-10.

613 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis
614 correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 1993; 143: 401-9.

615 Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--
616 correlation in invasive breast carcinoma. N Engl J Med, 1991; 324: 1-8.

617 Williams JL, Shea M, Furlan AJ, Little JR, Jones SC. Importance of freezing time when
618 iodoantipyrine is used for measurement of cerebral blood flow. Am J Physiol, 1991; 261:
619 H252-6.

620 Wu EX, Tang H, Jensen JH. High-resolution MR imaging of mouse brain
621 microvasculature using the relaxation rate shift index Q. NMR Biomed, 2004; 17: 507-
622 12.

623 Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW,
624 McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary
625 but not sufficient for production and growth of brain metastasis. *Cancer Res*, 2000; 60:
626 4959-67.

627

628

Graphical Abstract:

Vascular density varies significantly between brain regions and between healthy and diseased tissue. However, current methods are arduous and time consuming. Herein we present a rapid simple method to quantify vascular density in brain. Normal brain

vasculature is seen with indocyanine green fluorescence within the image.